GG

Geeta Gangwani

Active Director Director DIN 00234099
DIN 00234099 First appointment Dec 2002 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2002
Shareholding value •••• Premium profile

About Geeta Gangwani

Data last updated:

Geeta Gangwani is a Director at Nikem Drugs Private Limited (since 2002). The company operates in Pharma. Nikem Drugs Private Limited reported revenue of ₹4.46 Cr (FY 2025).

DIN 00234099
Primary Designation Director
Industry Pharma
First Appointment 30 Dec 2002
Oldest Company Age 23 yrs
Largest company Nikem Drugs Private Limited · ₹4.46 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nikem Drugs Private Limited U24232MP2002PTC015469
Director30 Dec 20022002₹4.46 Cr (FY 2025)Active

Board colleagues of Geeta Gangwani

NameDINCompanyDesignation
Rajesh Gangwani00234068Nikem Drugs Private LimitedDirector

Directorship timeline

Open interactive timeline →
Nikem Drugs Private Limited
Premium access

Shareholding and investment profile for Geeta Gangwani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Geeta Gangwani

Geeta Gangwani currently holds 1 directorship: Nikem Drugs Private Limited (Director, since 30 Dec 2002, revenue ₹4.46 Cr (FY 2025)).

Geeta Gangwani was first appointed on 30 Dec 2002 as Director at Nikem Drugs Private Limited.

The current boards of Geeta Gangwani's companies include Rajesh Gangwani (Nikem Drugs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available